Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
You are here
Most Viewed Papers
Food and Drug Administration drug insert for Campath (alemtuzumab)
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity.
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Delayed visual evoked response in optic neuritis.
B cells and multiple sclerosis.
Recent advances in the drug discovery of metabotropic glutamate receptor 4 (mGluR4) activators for the treatment of CNS and non-CNS disorders.
The neuroendocrine axis in patients with multiple sclerosis.
The environment and disease: association or causation?
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Patient page. Multiple sclerosis and vitamin D.
Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis.
"Undiagnosing" multiple sclerosis: The challenge of misdiagnosis in MS.
Teriflunomide added to interferon-β in relapsing multiple sclerosis: A randomized phase II trial.
The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Microvesicles: novel biomarkers for neurological disorders.
Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.
Masitinib mesylate application for conditional approval
A timing-of-birth effect on multiple sclerosis clinical phenotype.
MRI as an outcome in multiple sclerosis clinical trials.
Vitamin D: a natural inhibitor of multiple sclerosis.
Multiple sclerosis: an immune or neurodegenerative disorder?
The natural history of primary progressive MS in British Columbia, Canada.